At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
76 of 180 long COVID-associated genes also linked to ME
It's an acquisition that aims at forming one of the US's largest oncology trial networks
MRI is particularly valuable in pediatric care due to its non-invasive nature
Growing patent filings and tier-2 innovators reflect expanding national research base
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Subscribe To Our Newsletter & Stay Updated
